Methods of producing or providing metabolites of pathways associated with the gut-brain axis

The administration of Akkermansia muciniphila composition addresses the challenge of producing and providing metabolites for the GABA shunt, Kynurenine/IDO, and Indole/AHR pathways, effectively treating gut-brain axis disorders by increasing neurotransmitter levels and reducing symptoms of depression and anxiety.

WO2024249859A1PCT designated stage expired Publication Date: 2024-12-05PENDULUM THERAPEUTICS INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/032000
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-31
Filing Date
2024-05-31
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current methods fail to effectively produce and provide metabolites associated with the GABA shunt, Kynurenine/IDO, and Indole/AHR pathways, which are crucial for addressing gut-brain axis disorders, particularly in treating conditions like depression and anxiety by modulating neurotransmitter levels.

Method used

Administering a microbial composition comprising Akkermansia muciniphila or its supernatant, which produces and provides metabolites such as glutamate, GABA, succinate, xanthurenic acid, tryptophan, and indole-3-acetic acid, thereby targeting the GABA shunt, Kynurenine/IDO, and Indole/AHR pathways.

Benefits of technology

The administration of Akkermansia muciniphila composition effectively increases the levels of these metabolites in the subject, potentially treating gut-brain axis disorders by enhancing neurotransmitter production and reducing symptoms of depression and anxiety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024032000_05122024_PF_FP_ABST
    Figure US2024032000_05122024_PF_FP_ABST
Patent Text Reader

Abstract

Provided are methods of producing one or more metabolites of the GABA shunt pathway, the Kynurenine / IDO pathway, and / or the Indole / AHR pathway. In some embodiments, the methods comprise administering to a subject a microbial composition comprising Akkermansia muciniphila and / or an Akkermansia muciniphila supernatant or fraction thereof. According to some embodiments, the composition is administered orally. In certain embodiments, prior to the administering, the subject has been identified as having a gut-brain axis disorder, and wherein the method is for treating the gut-brain axis disorder. In certain embodiments, one or more metabolites of the GABA shunt pathway are produced, comprising one or more of glutamate, GABA, succinate, alpha-ketoglutarate, succinic semialdehyde, NAD, and NADH. In some instances, one or more metabolites of the Kynurenine / IDO pathway and / or the Indole / AHR pathway are produced comprising one or more of xanthurenic acid, picolinic acid, tryptophan, indole-3-acetic acid (IAA), indole-3-acetaldehyde (IAAId), Trytophol, and indole.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] METHODS OF PRODUCING O PROVIDING METABOLITES OF PATHWAYS ASSOCIATED WITH THE GUT-BRAIN AXIS

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 505,147, filed May 31 , 2024, which application is incorporated herein by reference in its entirety.

[0004] SUMMARY

[0005] Provided are methods of producing or providing one or more metabolites of the GABA shunt pathway, the Kynurenine / IDO pathway, and / or the Indole / AHR pathway. In some embodiments, the methods comprise administering to a subject a microbial composition comprising Akkermansia muciniphila and / or an Akkermansia muciniphila supernatant or fraction thereof. According to some embodiments, the composition is administered orally. In certain embodiments, prior to the administering, the subject has been identified as having a gut-brain axis disorder, and wherein the method is for treating the gut-brain axis disorder. In certain embodiments, one or more metabolites of the GABA shunt pathway are produced or provided, wherein the one or more metabolites of the GABA shunt pathway comprise one or more of glutamate, GABA, succinate, alpha-ketoglutarate, succinic semialdehyde, NAD, and NADH. In some instances, one or more metabolites of the Kynurenine / IDO pathway and / or the Indole / AHR pathway are produced or provided, wherein the one or more metabolites of the Kynurenine / IDO pathway and / or the Indole / AHR pathway comprise one or more of xanthurenic acid, picolinic acid, tryptophan, indole-3-acetic acid (IAA), indole-3-acetaldehyde (lAAId), Trytophol, and indole.

[0006] BRIEF DESCRIPTION OF THE FIGURES

[0007] FIG. 1 : Method demonstrating growth of A. muciniphila under growth conditions and the transcriptomics and metabolomic studies performed on the cell fractions and supernatants, respectively, during exponential or stationary phase.

[0008] FIG. 2: Data demonstrating A. muciniphila growth.

[0009] FIG. 3: Data demonstrating higher RNA levels of the genes responsible for the production of GABA and Tryptophan during the initial exponential phase (5h) of A. muciniphila growth.

[0010] FIG. 4A: Plot demonstrating signal intensity in the growth medium with or without A. muciniphila ; FIG. 4B: Data demonstrating database matching using curated database of >248,000 compounds; FIGS. 4C-4D: Data Validation by MS / MS Fragmentation of the molecule; FIGS. 4E-4G: Data demonstrating validation of GABA identification using peak identification, chemical formula validation and mass to charge ratio validation.

[0011] FIGS. 5A-5B: Data demonstrating that A. muciniphila produces glutamate, GABA and other metabolites on the GABA shunt pathway.

[0012] FIGS. 6A-6B: Data demonstrating A. muciniphila produces Tryptophan and a set of metabolites from the Kynurenine / IDO pathway and the Indole / AHR pathway.

[0013] FIG. 7A: Clinical study overview including especially the ITT (n = 76) and PP (n = 58) participant totals; FIG. 7B: Data demonstrating higher levels of metabolites from the Tryptophan and Kynurenine pathway in the plasma of subjects to whom A. muciniphila was administered.

[0014] DETAILED DESCRIPTION

[0015] Before the methods and compositions of the present disclosure are described in greater detail, it is to be understood that the methods and compositions are not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the methods and compositions will be limited only by the appended claims.

[0016] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the methods and compositions. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the methods and compositions, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the methods and compositions.

[0017] Certain ranges are presented herein with numerical values being preceded by the term “about.” The term “about” is used herein to provide literal support for the exact number that it precedes, as well as a number that is near to or approximately the number that the term precedes. In determining whether a number is near to or approximately a specifically recited number, the near or approximating unrecited number may be a number which, in the context in which it is presented, provides the substantial equivalent of the specifically recited number. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the methods and compositions belong. Although any methods and compositions similar or equivalent to those described herein can also be used in the practice or testing of the methods and compositions, representative illustrative methods and compositions are now described.

[0018] All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the materials and / or methods in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present methods and compositions are not entitled to antedate such publication, as the date of publication provided may be different from the actual publication date which may need to be independently confirmed.

[0019] It is noted that, as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.

[0020] It is appreciated that certain features of the methods and compositions, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the methods and compositions, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination. All combinations of the embodiments are specifically embraced by the present disclosure and are disclosed herein just as if each and every combination was individually and explicitly disclosed, to the extent that such combinations embrace operable processes and / or compositions. In addition, all sub-combinations listed in the embodiments describing such variables are also specifically embraced by the present methods and compositions and are disclosed herein just as if each and every such sub-combination was individually and explicitly disclosed herein.

[0021] As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present methods. Any recited method can be carried out in the order of events recited or in any other order that is logically possible.

[0022] METHODS OF PRODUCING METABOLITES

[0023] Provided are methods of producing one or more metabolites of the GABA shunt pathway, the Kynurenine / IDO pathway, and / or the Indole / AHR pathway, the methods comprise administering to the subject a microbial composition comprising Akkermansia muciniphila and / or an Akkermansia muciniphila supernatant or fraction thereof. According to some embodiments, the composition is administered orally. In certain embodiments, prior to the administering, the subject has been identified as having a gut-brain axis disorder, and wherein the method is for treating the gut-brain axis disorder. In certain embodiments, one or more metabolites of the GABA shunt pathway produced, comprising one or more of glutamate, GABA, succinate, alphaketoglutarate, succinic semialdehyde, NAD, and NADH. In certain embodiments, one or more metabolites of the Kynurenine / IDO pathway and / or the Indole / AHR pathway are produced comprising one or more of Xanthurenic acid, Picolinic acid, Tryptophan, lndole-3-acetic acid (IAA), indole-3-acetaldehyde (lAAId), Trytophol, and Indole.

[0024] Details regarding embodiments of the methods of the present disclosure will now be described.

[0025] According to some embodiments, the methods comprise administering to the subject a composition comprising Akkermansia muciniphila. Akkermansia muciniphila is a gram negative, strict anaerobe that can play a role in mucin degradation. Akkermansia muciniphila can serve as a primary fermenter, and in some cases, be combined with any one or more of the secondary fermenters. In certain embodiments, if the composition comprises one or more bacterial strains in addition to the Akkermansia muciniphila, then the Akkermansia muciniphila constitutes at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of the bacteria in the composition. According to some embodiments, the composition comprises microbes consisting essentially of, or consisting of, the Akkermansia muciniphila.

[0026] Individual doses of the composition may include, as to any one of the one or more microbial populations (e.g., Akkermansia muciniphila) included in a given dose, between about 1 x107and 1 x1015CFUs per dose. In some cases, the administration will be at least 1 x107CPUs of the microbes per dose, at least 1 x108CFUs per dose, at least 1 x109CFUs per dose, at least 1 x1010CFUs per dose, at least 1 x1011CFUs per dose, at least 1 x1012CFUs per dose, at least 1 x1013CFUs per dose, at least 1 x1014CFUs per dose, or mores. When the methods comprise administering to the subject a composition comprising Akkermansia muciniphila, the composition may be administered via any suitable route of administration. Non-limiting examples of suitable routes of administration include oral and topical administration. For example, when the methods comprise administering to the subject a composition comprising Akkermansia muciniphila, in some instances, the administering is by oral administration. In certain embodiments, when administered orally, the composition is in pill form. Non-limiting examples of such formulations include tablets, capsules, or the like.

[0027] In some embodiments, the microbial composition is formulated as an enteric-coated pill or capsule for oral administration. In some embodiments, the microbial composition is formulated for delivery of the microbes to the ileum region of a subject. In some embodiments, the microbial composition is formulated for delivery of the microbes to the colon region (e.g. upper colon) of a subject. In some embodiments, the microbial composition is formulated for delivery of the microbes to the ileum and colon regions of a subject.

[0028] An enteric-coating can protect the contents of the oral formulation, for example, pill or capsule, from the acidity of the stomach and provide delivery to the ileum and / or upper colon regions. Non-limiting examples of enteric coatings include pH sensitive polymers (e.g., eudragit FS30D), methyl acrylate-methacrylic acid copolymers, cellulose acetate succinate, hydroxy propyl methyl cellulose phthalate, hydroxy propyl methyl cellulose acetate succinate (e.g., hypromellose acetate succinate), polyvinyl acetate phthalate (PVAP), methyl methacrylatemethacrylic acid copolymers, shellac, cellulose acetate trimellitate, sodium alginate, zein, other polymers, fatty acids, waxes, shellac, plastics, and plant fibers. In some embodiments, the enteric coating is formed by a pH sensitive polymer. In some embodiments, the enteric coating is formed by Eudragit FS30D.

[0029] The enteric coating can be designed to dissolve at any suitable pH. In some embodiments, the enteric coating is designed to dissolve at a pH greater than about pH 6.5 to about pH 7.0. In some embodiments, the enteric coating is designed to dissolve at a pH greater than about pH 6.5. In some embodiments, the enteric coating is designed to dissolve at a pH greater than about pH 7.0. The enteric coating can be designed to dissolve at a pH greater than about: 5, 5.1 , 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1 , 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1 , 7.2, 7.3, 7.4, or 7.5 pH units.

[0030] According to some embodiments, when administered orally, the composition is a food, drink, dietary supplement, food supplement, or food additive. Non-limiting examples of food and drinks where the microbial compositions can be incorporated include, for example, bars, shakes, juices, infant formula, beverages, frozen food products, fermented food products, and cultured dairy products such as yogurt, yogurt drink, cheese, acidophilus drinks, and kefir.

[0031] According to some embodiments of the methods of the present disclosure, the composition further comprises a prebiotic. In some instances, the composition may further comprise a prebiotic selected from complex carbohydrates, complex sugars, resistant dextrins, resistant starch, amino acids, peptides, nutritional compounds, biotin, polydextrose, fructooligosaccharide (FOS), galactooligosaccharides (GOS), inulin, starch, lignin, psyllium, chitin, chitosan, gums (e.g. guar gum), high amylose cornstarch (HAS), cellulose, -glucans, hemi-celluloses, lactulose, mannooligosaccharides, mannan oligosaccharides (MOS), oligofructose-enriched inulin, oligofructose, oligodextrose, tagatose, transgalactooligosaccharide, pectin, resistant starch, xylooligosaccharides (XOS), and any combination thereof. In some embodiments, said prebiotic is inulin.

[0032] By Akkermansia muciniphila “supernatant” is meant a medium in which Akkermansia muciniphila has been cultured. As demonstrated herein, during culture, Akkermansia muciniphila secretes the products of gut-brain axis genes (e.g., gadB, gadC, glsA, tryptophan synthetase gene etc.) into the culture medium. In certain embodiments, a fraction of an Akkermansia muciniphila supernatant comprises, consists essentially of, or consists of, one or more of the gutbrain axis genes. Approaches for obtaining a supernatant fraction of interest are known and include centrifugation, elutriation, chromatography, and the like. Moreover, approaches for determining whether a fraction comprises a neurotransmitter of interest that is effective in treating a gut-brain axis disorder are available and include, e.g., mass spectrometry, an assay for measuring levels of gut-brain axis genes, an assay for metabolite levels from culturing A.muciniphila, and any combination thereof. Non-limiting examples of approaches for performing mass spectrometry and assays for RNA levels of gut-brain axis genes and metabolite secretion levels are provided in the Experimental section herein.

[0033] When the methods comprise administering to the subject a microbial composition comprising an Akkermansia muciniphila supernatant or fraction thereof, the microbial composition may be administered via any suitable route of administration. Non-limiting examples of suitable routes of administration include oral administration or topical administration. For example, when the methods comprise administering to the subject a microbial composition comprising an Akkermansia muciniphila or Akkermansia muciniphila supernatant or fraction thereof, in some instances, the administering is by oral administration. Any of the microbial compositions administered according to the methods of the present disclosure may include additional components, including but not limited to, at least one preservative. In particular embodiments, the composition may contain an effective amount of a preservative. An “effective” amount of a preservative is any amount that preserves or increases the shelf life of the composition beyond what would be obtained if the preservative were not present in the formulation. Examples of such preservatives include, but are not limited to, Vitamin E, Vitamin C, butylatedhydroxyanisole (BHA). butylatedhydroxytoluene (BHT), disodium ethylenediaminetetraacetic acid (EDTA), polyphosphates, citric acid, benzoates, sodium benzoate, sorbates, propionates, and nitrites.

[0034] A variety of subjects are treatable according to the methods of the present disclosure. The term “subject” as used herein refers to any living organism, including, but not limited to, humans, nonhuman primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats, rabbits and guinea pigs, and the like. The term does not denote a particular age or sex. In certain embodiments, the subject is human.

[0035] According to some embodiments, the subject (e.g., a human subject) has a gut-brain axis disorder. In some instances, prior to the administering, the subject has been identified as having a gut-brain axis disorder. In certain embodiments, prior to the administering, the subject has been identified as having a gut-brain axis disorder, and the method is for treating the gut-brain axis disorder. According to some embodiments, the gut-brain axis disorder is a disorder related to the bidirectional communication between the central and the enteric nervous system, linking emotional and cognitive centers of the brain with peripheral intestinal functions. In the absence of a healthy microbial colonization (in the gut), an altered expression and turnover of neurotransmitters in both central and peripheral nervous systems have been noted and studies have also shown alterations of gut sensory-motor functions, consisting in delayed gastric emptying and intestinal transit, reduced migrating motor complex cyclic recurrence and distal propagation, and enlarged cecal size. Further, neuromuscular abnormalities are associated with a reduction in gene expression of enzymes involved in the synthesis and transport of neurotransmitters, as well as in that of muscular contractile proteins. Reduction in neurotransmitter production as such that of gamma-Aminobutyric acid (GABA), tryptophan, kynurenine, serotonin, melatonin, histamine and acetylcholine can lead directly or indirectly to one or more gut-brain axis disorders. For instance, reduced a disrupted kynurenine-tryptophan pathway results in neuro-disorders such as depression, schizophrenia, neurodegenerative diseases to name a few and can lead to immune system activation and accumulation of potentially neurotoxic compounds. See, e.g., www.ncbi.nlm.nih.gov / pmc / articles / PMC4482796 / .

[0036] Most commonly, the association of dysbiosis with central nervous disorders (i.e. autism, anxiety-depressive behaviors) and functional gastrointestinal disorders are well known examples of the disorders caused by disruptions in the gut-brain axis. In some instances, the gut-brain axis disorder is anxiety. In some instances, the gut-brain axis disorder is depression. In some embodiments, the subject has major depressive disorder (MDD). MDD is a debilitating illness characterized by neuroanatomical and functional alterations in limbic structures, notably the prefrontal cortex (PFC), that can be precipitated by exposure to chronic stress. MDD patients and chronically stressed animals show a reduction in GABA and GAD67 levels in the brain, decreased expression of GABAergic interneuron markers, and alterations in GABAA and GABAB receptor levels. Fogaga et al. (2019) Front. Cell. Neurosci. doi.org / 10.3389 / fncel.2019.00087.

[0037] According to the methods of the present disclosure, the composition is administered in an amount effective to treat the gut-brain axis disorder. By “effective amount” is meant a dosage sufficient to produce a desired result, e.g., an amount sufficient to effect beneficial or desired therapeutic (including prophylactic) results, such as the prevention or a reduction in a symptom of a gut-brain axis disorder (e.g., depression, anxiety, or both), as compared to a control. In some embodiments, the effective amount is sufficient to slow the progression of, or reduce, one or more symptoms of gut-brain axis disorder selected from ..., and / or the like. According to some embodiments, the effective amount slows the progression of, or reduces, one or more of such symptoms by 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, or 100% or more, as compared to the one or more symptoms in the absence of the administration of the composition.

[0038] An effective amount can be administered in one or more administrations. In some cases, the methods comprise administration of multiple doses over a period of time. In certain embodiments, administration may comprise administration of 1 , 2, 3, 4, 5, 6 or more doses over the period of a day. In some cases, such daily administration may occur 1 day, 2 days, 3 days, 4 days, 5 days, 6 days or 7 days during a week. In some cases, such weekly administration may occur over the course of 1 week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 10 weeks, 12 weeks or longer. In some cases, such longer term administration may occur over the course of 1 month, 2 months, 3 months, 4 months, 5, months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months or longer. In some cases administration may be ongoing in order to maintain effects of such treatment, e.g., with the above described administration occurring over the course of 1 year, 2 years, 3 years or longer. For purposes of completeness, non-limiting aspects and embodiments of the present disclosure are further disclosed in the following numbered clauses.

[0039] 1 . A method of producing or providing one or more metabolites of the GABA shunt pathway, the Kynurenine / IDO pathway, and / or the Indole / AHR pathway in a subject in need thereof, the method comprising administering to the subject a microbial composition comprising Akkermansia muciniphila and / or an Akkermansia muciniphila supernatant or fraction thereof.

[0040] 2. The method according to clause 1 , wherein the microbial composition comprises Akkermansia muciniphila.

[0041] 3. The method according to clause 2, wherein if the microbial composition comprises one or more bacterial strains in addition to the Akkermansia muciniphila, then the Akkermansia muciniphila constitutes at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of the bacterial strains in the composition.

[0042] 4. The method according to clause 2, wherein the microbial composition comprises microbes consisting essentially of, or consisting of, the Akkermansia muciniphila.

[0043] 5. The method according to any one of clauses 1 to 4, wherein the administering is by oral administration.

[0044] 6. The method according to clause 5, wherein the microbial composition is in pill form.

[0045] 7. The method according to clause 6, wherein the pill is a tablet or capsule.

[0046] 8. The method according to clause 5, wherein the microbial composition is a food, drink, dietary supplement, food supplement, or food additive.

[0047] 9. The method according to any one of clauses 1 to 8, wherein one or more metabolites of the GABA shunt pathway are produced, and wherein the one or more metabolites of the GABA shunt pathway comprise one or more of glutamate, GABA, succinate, alpha-ketoglutarate, succinic semialdehyde, NAD, and NADH.

[0048] 10. The method according to any one of clauses 1 to 8, wherein one or more metabolites of the Kynurenine / IDO pathway and / or the Indole / AHR pathway are produced, and wherein the one or more metabolites of the Kynurenine / IDO pathway and / or the Indole / AHR pathway comprise one or more of Xanthurenic acid, Picolinic acid, Tryptophan, lndole-3-acetic acid (IAA), indole-3-acetaldehyde (lAAId), Trytophol, and Indole.

[0049] 11 . The method according to any one of clauses 1 to 10, wherein the microbial composition comprises a preservative. 12. The method according to any one of clauses 1 to 11 , wherein prior to the administering, the subject has been identified as having a gut-brain axis disorder, and wherein the method is for treating the gut-brain axis disorder.

[0050] 13. The method according to clause 12, wherein the gut-brain axis disorder is depression, anxiety, or a combination thereof.

[0051] 14. The method according to any one of clauses 1 to 13, wherein the microbial composition further comprises at least one of the microbes selected from the group consisting of: Anaerostipes caccae, Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium infantis, Bifidobacterium longum, Butyrivibrio fibrisolvens, Clostridium acetobutylicum, Clostridium aminophilum, Clostridium beijerinckii, Clostridium butyricum, Clostridium colinum, Clostridium coccoides, Clostridium indolis, Clostridium nexile, Clostridium orbiscindens, Clostridium propionicum, Clostridium xylanolyticum, Enterococcus faecium, Eubacterium hallii, Eubacterium rectale, Fibrobacter succinogenes, Oscillospira guilliermondii, Roseburia cecicola, Roseburia inulinivorans, Ruminococcus jlavefaciens, Ruminococcus gnavus, Ruminococcus obeum, Stenotrophomonas nitritireducens, Streptococcus cremoris, Streptococcus faecium, Streptococcus infantis, Streptococcus mutans, Streptococcus thermophilus, Anaerofustis stercorihominis, Anaerostipes hadrus, Anaerotruncus colihominis, Clostridium sporogenes, Clostridium tetani, Coprococcus eutactus, Eubacterium cylindroides, Eubacterium dolichum, Eubacterium ventriosum, Eubacterium hallii, Roseburia faeccis, Roseburia hominis, Roseburia intestinalis, Lactobacillus bifidus, Acidaminococcus fermentans, Acidaminococcus intestine, Blautia hydrogenotrophica, Citrobacter amalonaticus, Citrobacter freundii, Clostridium aminobutyricum Clostridium bartlettii, Clostridium cochlearium, Clostridium kluyveri, Clostridium limosum, Clostridium malenominatum, Clostridium pasteurianum, Clostridium peptidivorans, Clostridium saccharobutylicum, Clostridium sporosphaeroides, Clostridium sticklandii, Clostridium subterminale, Clostridium symbiosum, Clostridium tetanomorphum, Eubacterium oxidoreducens, Eubacterium pyruvativorans, Methanobrevibacter smithii, Morganella morganii, Peptoniphilus asaccharolyticus, and any combination thereof.

[0052] 15. The method according to any one of clauses 1 to 14, wherein the microbial composition further comprises Bifidobacterium infantis, Clostridium beijerinckii, Clostridium butyricum, Eubacterium hallii, or any combination thereof. 16. The method according to clause 15, wherein the microbial composition further comprises each of Bifidobacterium infantis, Clostridium beijerinckii, Clostridium butyricum, and Eubacterium hallii.

[0053] The following example is offered by way of illustration and not by way of limitation.

[0054] EXPERIMENTAL

[0055] Demonstrated herein is the production of neurotransmitters by A. muciniphila. Transcriptomic and metabolomic approaches established that A. muciniphila expresses and secretes metabolites of the GABA and tryptophan pathways.

[0056] Provided herein are experimental details of studies performed to indicate the utility of live A. muciniphila in regulating the GABA and Kynurenine pathways which are important targets to address neurological conditions like depression and anxiety.

[0057] High levels of RNA from the tryptophan / kynurenine pathway and GABA / Glutamate pathway were measured, including that of genes such as gadB, gadC and glsA. It was observed that the gene expression was high during the exponential growth phase of A.muciniphila.

[0058] Using metabolomics, it was demonstrated that A.muciniphila produces all of the metabolites of the GABA shunt as well as intermediates of the tryptophan pathway.

[0059] Also provided herein are clinical trial results of subjects receiving a probiotic formulation comprising A. muciniphila who showed higher plasma levels of Kynurenine metabolites.

[0060] Exemplary data is shown in FIGs. 1 -7.

[0061] Accordingly, the preceding merely illustrates the principles of the present disclosure. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the invention and are included within its spirit and scope. Furthermore, all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the invention and the concepts contributed by the inventors to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Moreover, all statements herein reciting principles, aspects, and embodiments of the invention as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. The scope of the present invention, therefore, is not intended to be limited to the exemplary embodiments shown and described herein.

Claims

WHAT IS CLAIMED IS:1 . A method of producing or providing one or more metabolites of the GABA shunt pathway, the Kynurenine / IDO pathway, and / or the Indole / AHR pathway in a subject in need thereof, the method comprising administering to the subject a microbial composition comprising Akkermansia muciniphila and / or an Akkermansia muciniphila supernatant or fraction thereof.

2. The method according to claim 1 , wherein the microbial composition comprises Akkermansia muciniphila.

3. The method according to claim 2, wherein if the microbial composition comprises one or more bacterial strains in addition to the Akkermansia muciniphila, then the Akkermansia muciniphila constitutes at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of the bacterial strains in the composition.

4. The method according to claim 2, wherein the microbial composition comprises microbes consisting essentially of, or consisting of, the Akkermansia muciniphila.

5. The method according to any one of claims 1 to 4, wherein the administering is by oral administration.

6. The method according to claim 5, wherein the microbial composition is in pill form.

7. The method according to claim 6, wherein the pill is a tablet or capsule.

8. The method according to claim 5, wherein the microbial composition is a food, drink, dietary supplement, food supplement, or food additive.

9. The method according to any one of claims 1 to 8, wherein one or more metabolites of the GABA shunt pathway are produced, and wherein the one or more metabolites of the GABA shunt pathway comprise one or more of glutamate, GABA, succinate, alpha-ketoglutarate, succinic semialdehyde, NAD, and NADH.

10. The method according to any one of claims 1 to 8, wherein one or more metabolites of the Kynurenine / IDO pathway and / or the Indole / AHR pathway are produced, and wherein the one or more metabolites of the Kynurenine / IDO pathway and / or the Indole / AHR pathway comprise one or more of Xanthurenic acid, Picolinic acid, Tryptophan, lndole-3-acetic acid (IAA), indole-3-acetaldehyde (lAAId), Trytophol, and Indole.11 . The method according to any one of claims 1 to 10, wherein the microbial composition comprises a preservative.

12. The method according to any one of claims 1 to 11 , wherein prior to the administering, the subject has been identified as having a gut-brain axis disorder, and wherein the method is for treating the gut-brain axis disorder.

13. The method according to claim 12, wherein the gut-brain axis disorder is depression, anxiety, or a combination thereof.

14. The method according to any one of claims 1 to 13, wherein the microbial composition further comprises at least one of the microbes selected from the group consisting of: Anaerostipes caccae, Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium infantis, Bifidobacterium longum, Butyrivibrio fibrisolvens, Clostridium acetobutylicum, Clostridium aminophilum, Clostridium beijerinckii, Clostridium butyricum, Clostridium colinum, Clostridium coccoides, Clostridium indolis, Clostridium nexile, Clostridium orbiscindens, Clostridium propionicum, Clostridium xylanolyticum, Enterococcus faecium, Eubacterium hallii, Eubacterium rectale, Fibrobacter succinogenes, Oscillospira guilliermondii, Roseburia cecicola, Roseburia inulinivorans, Ruminococcus jlavefaciens, Ruminococcus gnavus, Ruminococcus obeum, Stenotrophomonas nitritireducens, Streptococcus cremoris, Streptococcus faecium, Streptococcus infantis, Streptococcus mutans, Streptococcus thermophilus, Anaerofustis stercorihominis, Anaerostipes hadrus, Anaerotruncus colihominis, Clostridium sporogenes, Clostridium tetani, Coprococcus eutactus, Eubacterium cylindroides, Eubacterium dolichum, Eubacterium ventriosum, Eubacterium hallii, Roseburia faeccis, Roseburia hominis, Roseburia intestinalis, Lactobacillus bifidus, Acidaminococcus fermentans, Acidaminococcus intestine, Blautia hydrogenotrophica, Citrobacter amalonaticus, Citrobacter freundii, Clostridium aminobutyricum Clostridium bartlettii, Clostridium cochlearium, Clostridium kluyveri,Clostridium limosum, Clostridium malenominatum, Clostridium pasteurianum, Clostridium peptidivorans, Clostridium saccharobutylicum, Clostridium sporosphaeroides, Clostridium sticklandii, Clostridium subterminale, Clostridium symbiosum, Clostridium tetanomorphum, Eubacterium oxidoreducens, Eubacterium pyruvativorans, Methanobrevibacter smithii, Morganella morganii, Peptoniphilus asaccharolyticus, and any combination thereof.

15. The method according to any one of claims 1 to 14, wherein the microbial composition further comprises Bifidobacterium infantis, Clostridium beijerinckii, Clostridium butyricum, Eubacterium hallii, or any combination thereof.

16. The method according to claim 15, wherein the microbial composition further comprises each of Bifidobacterium infantis, Clostridium beijerinckii, Clostridium butyricum, and Eubacterium hallii.

Citation Information

Patent Citations

  • Use of akkermansia muciniphila for treating inflammatory conditions

    US20180296613A1

  • Compositions for modulating gut microflora populations, enhancing drug potency and treating cancer, and methods for making and using same

    US20210038654A1

  • Composition comprising pasteurized akkermansia muciniphila for the treatment or prevention of gut contractility disorders, in particular duodenal contraction amplitude disorder

    WO2023020831A1